Attach to Form 990 or Form 990-EZ.
See separate instructions.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization in col. (i) listed in your governing document? | (v) Did you notify the organization in col. (i) of your support? | (vi) Is the organization in col. (i) organized in the U.S.? | (vii) Amount of monetary support | |||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2009 | (b) 2010 | (c) 2011 | (d) 2012 | (e) 2013 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 150,769,181 | 160,093,433 | 156,880,684 | 146,497,371 | 146,698,221 | 760,938,890 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 150,769,181 | 160,093,433 | 156,880,684 | 146,497,371 | 146,698,221 | 760,938,890 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 44,359,603 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 716,579,287 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2009 | (b) 2010 | (c) 2011 | (d) 2012 | (e) 2013 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 150,769,181 | 160,093,433 | 156,880,684 | 146,497,371 | 146,698,221 | 760,938,890 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 1,354,102 | 2,037,946 | 4,402,201 | 4,000,400 | 4,044,153 | 15,838,802 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.).. | 0 | |||||
| 11 | Total support (Add lines 7 through 10). | 777,118,124 | |||||






Calendar year (or fiscal year beginning in) ![]() |
(a) 2009 | (b) 2010 | (c) 2011 | (d) 2012 | (e) 2013 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2009 | (b) 2010 | (c) 2011 | (d) 2012 | (e) 2013 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1 | ORGANIZATION'S MISSION SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. |
| FORM 990, PART III, LINE 4A | PROGRAM SERVICE ACCOMPLISHMENTS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE IS DEDICATED TO DISCOVERING THE FUNDAMENTAL MOLECULAR CAUSES OF DISEASE AND DEVISING THE INNOVATIVE THERAPIES OF TOMORROW. SANFORD-BURNHAM TAKES A UNIQUE, COLLABORATIVE APPROACH TO MEDICAL RESEARCH AND HAS ESTABLISHED MAJOR RESEARCH PROGRAMS IN CANCER, NEURODEGENERATION, DIABETES, AND INFECTIOUS, INFLAMMATORY, AND CHILDHOOD DISEASES. CANCER RESEARCH A NEW APPROACH TO TREATING BRAIN CANCER. MEDULLOBLASTOMA IS THE MOST COMMON MALIGNANT BRAIN CANCER IN CHILDREN. ALTHOUGH MANY PATIENTS CAN BE CURED WITH SURGERY, RADIATION, AND HIGH-DOSE CHEMOTHERAPY, SURVIVORS OFTEN SUFFER SEVERE LONG-TERM SIDE EFFECTS SUCH AS COGNITIVE AND DEVELOPMENTAL DISABILITIES DUE TO THE AGGRESSIVE TREATMENT. A RESEARCH TEAM LED BY DR. ROBERT WECHSLER-REYA DEVELOPED A NEW EXPERIMENTAL APPROACH TO TREATING MEDULLOBLASTOMA BY TARGETING CANCER STEM CELLS - THE CELLS THAT ARE CRITICAL FOR MAINTAINING TUMOR GROWTH. BY USING SMALL-MOLECULE INHIBITORS TO STOP THE ACTION OF ENZYMES THAT ARE ESSENTIAL FOR CELL-CYCLE PROGRESSION, THE RESEARCHERS WERE ABLE TO BLOCK THE GROWTH OF TUMOR CELLS FROM MICE AS WELL AS HUMANS. THESE FINDINGS, DESCRIBED IN A RECENT PAPER IN CANCER RESEARCH, STRONGLY SUPPORT THE NOTION OF COMBINING CONVENTIONAL CHEMOTHERAPY WITH CELL-CYCLE INHIBITORS TO IMPROVE THE EFFECTIVENESS OF THERAPY FOR MEDULLOBLASTOMA PATIENTS. A NEW TARGET FOR MELANOMA. PDK1 IS AN ENZYME THAT REGULATES A NUMBER OF PROCESSES IMPORTANT FOR NORMAL CELL FUNCTION. IN A RECENT PUBLICATION IN ONCOGENE, DR. ZE'EV RONAI'S LABORATORY PROVIDED THE FIRST GENETIC EVIDENCE SHOWING THE IMPORTANCE OF PDK1 IN MELANOMA. RONAI'S TEAM USED MICE THAT LACK THE PDK1 GENE TO SHOW THAT WITHOUT PDK1 GENE EXPRESSION, MELANOMA TUMORS RAPIDLY DEVELOP, BUT ARE SMALLER IN SIZE, HAVE SIGNIFICANT LOSS OF METASTASIS, AND THE MICE HAVE AN OVERALL PROLONGED SURVIVAL. IMPORTANTLY, WHEN THE TEAM OF RESEARCHERS USED A PDK1 INHIBITOR IN WILD-TYPE MICE, THEY WERE ABLE DELAY MELANOMA GENESIS AND METASTASIS-INDICATING THAT PHARMACOLOGICAL INTERVENTION MAY BLOCK THE DEVELOPMENT OF MELANOMA TUMORS. THESE FINDINGS ARE IMPORTANT BECAUSE THEY ESTABLISH THE IMPORTANCE OF PDK1 IN MELANOMA DEVELOPMENT AND METASTASIS AND SUGGEST THAT PDK1 INHIBITORS SHOULD BE CONSIDERED AS PART OF THE THERAPEUTIC REGIMENT FOR MELANOMA. SMIP004 AS A NOVEL TREATMENT FOR ADVANCED PROSTATE CANCER. A MAJOR HALLMARK OF CANCER CELLS IS THEIR ABILITY TO SURVIVE UNDER STRESSFUL CONDITIONS. A NEW STUDY SPEARHEADED BY DR. DIETER WOLF AND HIS TEAM REVEALS HOW A PROMISING ANTICANCER COMPOUND CALLED SMIP004 SPECIFICALLY KILLS PROSTATE CANCER CELLS BY COMPROMISING THEIR ABILITY TO WITHSTAND ENVIRONMENTAL STRESS. THE STUDY, RECENTLY PUBLISHED IN ONCOTARGET, UNCOVERS NOVEL MECHANISMS OF ANTICANCER ACTIVITY AND COULD LEAD TO THE DEVELOPMENT OF MORE EFFECTIVE THERAPIES FOR ADVANCED AND HARD-TO-TREAT FORMS OF PROSTATE CANCER, AS WELL AS OTHER TYPES OF CANCER. IN A PREVIOUS STUDY, WOLF AND HIS TEAM IDENTIFIED SMIP004 AS A PROMISING ANTICANCER AGENT WHEN THEY SCREENED FOR COMPOUNDS THAT SPECIFICALLY KILL PROSTATE CANCER CELLS WHILE SPARING NORMAL CELLS. BUT UNTIL NOW, EXACTLY HOW SMIP004 WORKS WAS UNKNOWN. NEW METABOLIC PATHWAY IMPLICATED IN CANCER AND METABOLIC DISORDERS. DECIPHERING THE BODY'S COMPLEX MOLECULAR PATHWAYS THAT LEAD TO DISEASE WHEN THEY MALFUNCTION IS HIGHLY CHALLENGING. DRS. MARIA DIAZ-MECO AND JORGE MOSCAT AND THEIR TEAMS NOW HAVE A MORE COMPLETE PICTURE OF ONE PARTICULAR PATHWAY THAT CAN LEAD TO CANCER AND DIABETES. IN THEIR STUDY, PUBLISHED BY MOLECULAR CELL, THE SCIENTISTS UNCOVERED HOW A PROTEIN CALLED P62 HAS A CASCADE AFFECT IN REGULATING CELL GROWTH IN RESPONSE TO THE PRESENCE OF NUTRIENTS SUCH AS AMINO ACIDS AND GLUCOSE. THE PROTEIN P62 INTERACTS WITH ANOTHER PROTEIN CALLED TRAF6 TO ACTIVATE A PROTEIN COMPLEX CALLED MTORC1. IN FACT, RESEARCHERS HAVE FOUND THAT MTORC1 IS HIGHLY ACTIVATED IN CANCER CELLS. THE PATHWAY THAT CONTROLS MTORC1 ACTIVATION IS ALSO IMPORTANT FOR METABOLIC HOMEOSTASIS. WHEN THE PATHWAY MALFUNCTIONS, METABOLIC DISORDERS SUCH AS DIABETES CAN RESULT AND TUMORS CAN PROGRESS. DISRUPTING THIS CHAIN MAY OFFER A NEW APPROACH TO TREATING DISEASE. DEGENERATIVE DISEASE PROGRAM A NEW MECHANISM THAT MAY CAUSE NEURONAL LOSS IN ALZHEIMER'S DISEASE. DR. HUAXI XU PUBLISHED A REPORT IN PLOS ONE THAT SUGGESTS AMYLOID PRECURSOR PROTEIN INTERACTS WITH NERVE GROWTH-FACTOR RECEPTORS ON THE SURFACE OF NEURONS, REDUCING NEURONAL SURVIVAL AND DIFFERENTIATION. THE FINDINGS REVEAL A POSSIBLE CONTRIBUTOR TO THE PATHOGENESIS OF ALZHEIMER'S DISEASE. IDENTIFICATION OF A SIGNALING PATHWAY THAT PREVENTS INFLAMMATORY BOWEL DISEASE (IBD). A GROWING BODY OF RESEARCH LINKS PROTEIN MISFOLDING TO INFLAMMATORY BOWEL DISEASE (IBD). MISFOLDED PROTEINS ARE DAMAGED PROTEINS THAT CAN BE CAUSED BY GENETIC MUTATIONS OR IN RESPONSE TO ENVIRONMENTAL CONDITIONS. DR. RANDAL KAUFMAN'S LABORATORY PUBLISHED FINDINGS IN INFLAMMATORY BOWEL DISEASES SHOWING THAT PHOSPHORYLATION OF THE REGULATORY PROTEIN ELF2-ALPHA IS REQUIRED FOR CELLS TO RESPOND TO MISFOLDED PROTEINS AND TO MAINTAIN THE MUCOUS CELL FUNCTIONS THAT LIMIT INFLAMMATION AND BACTERIAL INFECTIONS. THE FINDINGS BRING NEW INSIGHT INTO POTENTIAL AVENUES TO TREAT AND ALLEVIATE SYMPTOMS OF IBD. TRANSPLANTED STEM CELLS FOR PARKINSON'S DISEASE. DR. STUART LIPTON AND COLLEAGUES PUBLISHED WORK IN THE JOURNAL OF COMPARATIVE NEUROLOGY ON TRANSPLANTING HUMAN EMBRYONIC STEM CELL (HESC)-DERIVED NEURAL CELLS INTO THE BRAINS OF ANIMAL MODELS (RODENTS AND MONKEYS) OF PARKINSON'S DISEASE. THE BREAKTHROUGH TECHNOLOGY DESCRIBED IN THE STUDY IS THE FIRST REPORT OF TRANSPLANTATION AFTER PROGRAMMING THE STEM CELLS WITH A GENE CALLED MEF2C. MEF2C IS A GENE LOST IN PARKINSON'S AND EFFORTS TO REPLACE AND RESTORE MEF2C-GENE FUNCTION IS AN EMERGING APPROACH TO TREATING THE DISEASE. IMMUNITY AND PATHOGENESIS PROGRAM A NEW THERAPEUTIC TARGET FOR PSORIASIS. DR. CARL WARE AND COLLEAGUES HAVE IDENTIFIED THE B- AND T-LYMPHOCYTE ATTENUATOR (BTLA) INHIBITORY RECEPTOR AS A KEY FACTOR IN LIMITING INFLAMMATORY RESPONSES, PARTICULARLY IN THE SKIN. THE STUDY, PUBLISHED ONLINE IN IMMUNITY, PROVIDES CLARITY ON HOW T-CELLS GET FIRED UP TO PROTECT AGAINST PATHOGENS, AND THEN COOL DOWN TO RESTORE IMMUNE HOMEOSTASIS. WARE'S RESEARCH SHOWED THAT THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA-T (ROR GAMMA-T) NUCLEAR TRANSCRIPTION FACTOR WORKS WITH INTERLEUKIN (IL)-7 TO COORDINATE THE EXPRESSION OF BTLA, WHICH IN TURN REGULATES GAMMA-DELTA T-CELL RESPONSES. "IF A DRUG CAN SELECTIVELY ACTIVATE BTLA, WE PUT THE BRAKES ON GAMMA-DELTA T-CELLS AND GAIN CONTROL OF INFLAMMATION, PREVENT DAMAGE AND, IF POSSIBLE, ACHIEVE LONG-TERM DISEASE REMISSION," SAID WARE. MAPPING THE SHORT-CUT FOR HIV INFECTION. UNDERSTANDING HOW HIV EXPLOITS THE HUMAN CELL MACHINERY IS ESSENTIAL FOR DEVELOPING NOVEL STRATEGIES FOR LONG TERM TREATMENT. IN A NEW STUDY BY DR. SUMIT CHANDA, IN COLLABORATION WITH UC SAN DIEGO AND PUBLISHED ON PLOS ONE (ONLINE), THE RESEARCHERS DESCRIBE THE FIRST GLOBAL MAP OF THE HUMAN PROTEIN COMPLEXES INVOLVED IN HIV INFECTION. BY INTEGRATING DATA SETS ON PROTEINS AND GENES THE TEAM REVEALED NEW REGULATORY COMPONENTS OF PROTEINS THAT PLAY A ROLE IN HIV INFECTION. THE STUDY PROVIDES A RESOURCE FOR TRACKING TARGETING PROTEIN COMPLEXES AT DIFFERENT STAGES OF THE HIV LIFE CYCLE AND MAY ULTIMATELY LEAD TO A NEW THERAPEUTIC APPROACH OF TARGETING HUMAN PROTEINS TO TREAT THE DISEASE. PREVENTING AUTOIMMUNE DISEASES. B-CELL PRODUCTION IN BONE MARROW RESULTS IN THE GENERATION OF A VAST REPERTOIRE OF ANTIBODY-PRODUCING CELLS THAT COLLECTIVELY RECOGNIZE VIRTUALLY ANY FOREIGN ENTITY, INCLUDING PATHOGEN COMPONENTS. HOWEVER, THE RANDOM PROCESS OF ANTIBODY GENERATION ALSO PRODUCES B CELLS THAT IN TURN PRODUCE AUTOANTIBODIES THAT CAN RECOGNIZE "SELF-ANTIGENS," LEADING TO AUTOIMMUNE DESTRUCTION AS OCCURS IN LUPUS AND SOME TYPES OF ARTHRITIS. IN A RECENT PAPER IN THE JOURNAL OF IMMUNOLOGY, DR. ROBERT RICKERT'S LAB INVESTIGATED THE CELLULAR PROCESSES THAT CONTROL B-CELL TOLERANCE, WHICH PREVENTS B CELLS FROM PRODUCING ANTIBODIES TO SELF-ANTIGENS. THEY DEVELOPED A NOVEL EXPERIMENTAL MODEL TO SHOW THAT A SPECIALIZED CELL TYPE TERMED FOLLICULAR DENDRITIC CELLS (FDCS) IS EFFICIENT IN PRESENTING SELF-ANTIGENS AND ELIMINATING AUTOREACTIVE B CELLS TO SELF-ANTIGENS. THESE FINDINGS PROVIDE A NEW PERSPECTIVE ON HOW AUTOIMMUNE DISEASE MAY BE PREVENTED. |
| HUMAN GENETICS PROGRAM | RESEARCHERS REVEAL NEW CAUSE OF EPILEPSY. DR. YU YAMAGUCHI, IN COLLABORATION WITH SUNY DOWNSTATE MEDICAL CENTER, FOUND THAT DEFICIENCIES IN HYALURONAN, ALSO KNOWN AS HYALURONIC ACID OR HA, CAN LEAD TO SPONTANEOUS EPILEPTIC SEIZURES. THE STUDY WAS THE FIRST TO DEMONSTRATE THE IMPORTANT ROLE OF THIS UNIQUE MOLECULE IN BRAIN FUNCTIONS AND PROVIDES KEY INFORMATION THAT MAY LEAD TO NEW THERAPEUTIC APPROACHES FOR EPILEPSY. THE STUDY WAS PUBLISHED ON APRIL 30 IN THE JOURNAL OF NEUROSCIENCE. TEASING STEM CELLS TO REPLACE NEURONS IN PARKINSON'S DISEASE. DR. EVAN SNYDER AND COLLEAGUES PUBLISHED A STUDY IN STEM CELLS TRANSLATIONAL MEDICINE DESCRIBING ATTEMPTS TO INJECT HUMAN FETAL NEURAL STEM CELLS IN MONKEYS WITH PARKINSON'S DISEASE. THE STUDY RESULTS SHOW THAT INCLUDING A CRITICAL NEURON-DEVELOPMENT FACTOR WITH THE STEM CELL INJECTION DID NOT INCREASE THE PERCENTAGE OF DESIRED NEURONS AS EXPECTED, BUT DID SHOW THAT THE INJECTED CELLS BEGAN TO SEND OUT LONG PROJECTIONS. THE RESULTS INDICATE THAT TEASING STEM CELLS TO DEVELOP A LITTLE FARTHER ALONG THEIR NEURON PATHWAY BEFORE INJECTION MIGHT IMPROVE THE PROCESS OF REPLACING NEURONS AS A NEW APPROACH TO TREATING PARKINSON'S DISEASE. SUGAR: THE GOOD, THE BAD, AND THE UGLY. DR. HUDSON FREEZE'S LABORATORY HAS PUBLISHED THREE PAPERS DESCRIBING RARE DISORDERS CAUSED BY GENETIC DEFECTS IN THE PROCESS OF ATTACHING SUGAR MOLECULES TO PROTEINS. PATIENTS WITH THESE DISORDERS EXHIBIT MOTOR AND INTELLECTUAL DISABILITIES, SEIZURES, DEVELOPMENT DELAYS, AND OTHER SERIOUS CONDITIONS. THE STUDIES EXAMINE THE METABOLIC FATE OF INGESTING THE SUGAR MANNOSE TO COMPENSATE AND BOLSTER THERAPEUTIC STRATEGIES FOR TREATING THE DISORDERS. IN ONE STUDY, PUBLISHED IN THE JOURNAL GLYCOSYLATION, MOUSE MODELS OF THE DISEASE SHOWED IMPROVED IMMUNE FUNCTIONS WHEN GIVEN THE SUGAR MANNOSE AS A SUPPLEMENT. IN A SECOND STUDY PUBLISHED IN FASEB, THE RESEARCH TEAM SHOWED THAT MANNOSE SUPPLEMENTS IN PREGNANT-MOUSE MODELS OF THE DISEASE RESULT IN EYE DEFECTS AND REDUCED LITER SIZE-SUGGESTING CAUTION FOR THE HUMAN APPLICATION FOR MOTHERS AT RISK. DEVELOPMENT, AGING AND REGENERATION PROGRAM MUSCLE STEM CELL PROLIFERATION DYNAMICS. IN A RECENT ARTICLE IN DEVELOPMENT FROM DR. ALESSANDRA SACCO IN COLLABORATION WITH DR. ANDREW BRACK AT HARVARD, THE AUTHORS INVESTIGATED THE HETEROGENEITY OF SKELETAL MUSCLE STEM CELLS. THEY SHOW THAT SLOW PROLIFERATING MUSCLE STEM CELLS ARE FORMED AT BIRTH AND ARE ESSENTIAL FOR TISSUE MAINTENANCE AND REPAIR. THE TEAM IDENTIFIED CELL CYCLE INHIBITOR P27 AS A MAJOR REGULATOR OF THIS TISSUE REPAIR PROCESS. THEY WILL CONTINUE TO STUDY HOW THIS STEM CELL POPULATION IS MODIFIED UNDER MUSCLE-WASTING CONDITIONS AND EVALUATE IT AS A POTENTIAL CELLULAR TARGET FOR FUTURE THERAPEUTIC INTERVENTIONS AGAINST MUSCLE LOSS. REGENERATING MUSCLE IN DUCHENNE MUSCULAR DYSTROPHY: AGE MATTERS. THE LABORATORIES OF DRS. LORENZO PURI AND MARK MERCOLA PUBLISHED A PAPER IN GENES AND DEVELOPMENT THAT DETAILS HOW A CLASS OF DRUGS CALLED HDACIS DRIVE MUSCLE-CELL REGENERATION IN THE EARLY STAGES OF DYSTROPHIC MUSCLES, BUT FAILS TO WORK IN LATE STAGES. THE RESEARCH USED MOUSE MODELS OF DUCHENNE MUSCULAR DYSTROPHY (DMD) TO SHOW HOW HDACIS CREATE AN ENVIRONMENT CONDUCIVE FOR FIBRO-ADIPOGENETIC CELLS (FAPS) TO DIRECT MUSCLE REGENERATION. BUT AT SOME POINT, DMD PROGRESSES TO A PATHOLOGICAL POINT OF NO RETURN-BECOMING RESISTANT TO HDACIS. HDACIS ARE EPIGENETIC DRUGS THAT WORK BY MAKING GENES ACCESSIBLE TO THE CELL MACHINERY THAT TRANSCRIBES THE GENETIC CODE INTO PROTEINS. THE STUDY SUGGESTS A MOLECULAR MECHANISM FOR THE USE OF HDAC INHIBITORS IN THE TREATMENT OF DYSTROPHIC MUSCLES, SUCH AS IN DMD. BIOINFORMATICS AND STRUCTURAL BIOLOGY PROGRAM SHEDDING LIGHT ON KILLER ISLANDS. "PATHOGENICITY ISLANDS," ARE GENETIC ELEMENTS FOUND IN PATHOGENIC BACTERIA. THEY ARE OFTEN SHARED BETWEEN BACTERIA AND, IF PRESENT, THEY CONVEY SPECIFIC VIRULENCE ABILITIES TO BACTERIA CARRYING THEM. IN THE CASE OF GUT BACTERIUM BACTEROIDES FRAGILIS, PROTEINS ENCODED AT THESE ISLANDS CONTRIBUTE TO INFLAMMATORY DIARRHEA, ULCERATIVE COLITIS, AND INCREASED RISK OF COLORECTAL CANCER. DR. ALEX STRONGIN'S LAB CHARACTERIZED METALLOPROTEINASE II (MPII), A KEY PROTEASE ENCODED ON THE PATHOGENICITY ISLAND OF THE B. FRAGILIS GENOME. THE STUDY, PUBLISHED IN THE JOURNAL OF BIOLOGICAL CHEMISTRY, REVEALED THAT MPII LIKES TO "CUT" PROTEINS AT THE POINT BETWEEN TWO BASIC AMINO ACIDS AND BY DOING THIS IT CAN "REMODEL" THE NORMAL LUMINAL EPITHELIUM OF THE GASTROINTESTINAL TRACT, PAVING THE WAY FOR INFLAMMATION AND DISEASE BY DISRUPTING MEMBRANE STRUCTURE AND FUNCTION. HITTING TUBERCULOSIS WHERE IT HURTS. TUBERCULOSIS REMAINS A MAJOR CAUSE OF DEATH AROUND THE WORLD AND BECAUSE OF QUICKLY DEVELOPING DRUG RESISTANCE IT IS MAKING A COMEBACK, EVEN IN DEVELOPING COUNTRIES INCLUDING THE U.S. SANFORD-BURNHAM'S DR. ANDREI OSTERMAN, IN COLLABORATION WITH DR. E. RUBIN FROM HARVARD MEDICAL SCHOOL AND VERTEX PHARMACEUTICALS, PERFORMED EXPERIMENTS TO VALIDATE A NOVEL TARGET FOR ANTI-TUBERCULOSIS DRUGS. THE RESEARCH SOUGHT TO IDENTIFY NEW TARGETS WHICH WOULD BE EFFECTIVE AGAINST GROWING AS WELL AS PERSISTENT (DORMANT) INFECTIONS THAT REPRESENT A PARTICULAR CHALLENGE FOR ALL CURRENTLY AVAILABLE THERAPIES. A COMBINATION OF SYSTEMS-BIOLOGY MODELING OF MYCOBACTERIAL METABOLIC NETWORKS WITH TARGETED PROTEIN KNOCKDOWN AND METABOLOMICS TECHNIQUES SHOWED THAT TARGETING BIOSYNTHESIS OF NAD(H), AN ESSENTIAL COFACTOR IN ENERGY HOMEOSTASIS, WOULD LEAD TO EFFECTIVE THERAPIES AGAINST BOTH REPLICATING AND NON-REPLICATING M. TUBERCULOSIS BACTERIA. THE STUDY WAS PUBLISHED IN MBIO. SOME LIKE IT HOT. DR. ADAM GODZIK AND COLLEAGUES USED STRUCTURAL SYSTEMS BIOLOGY TO ANALYZE THE METABOLIC NETWORK OF BACTERIUM E. COLI TO ANSWER THE QUESTIONS: WHY IS E. COLI NOT A HEAT-LOVING ORGANISM, AND CAN IT BE CHANGED INTO A THERMOPHILE? MODELING AND ANALYZING THE THREE-DIMENSIONAL STRUCTURE OF ALL ENZYMES THAT FORM THE NODES OF THIS METABOLIC NETWORK ALLOWED RESEARCHERS TO IDENTIFY THE PARTS OF THE NETWORK THAT WOULD FAIL FIRST WITH RISING TEMPERATURE. THE PREDICTION WAS CONFIRMED BY PROVIDING E. COLI WITH A TARGETED METABOLITE MIXTURE TO COMPENSATE FOR THE FAILING ENZYMES. THIS STUDY, PUBLISHED IN SCIENCE, IS THE FIRST EXAMPLE OF CELL-LEVEL, INTEGRATED ANALYSIS OF THREE-DIMENSIONAL MODELS OF PROTEINS IN THE CONTEXT OF THE NETWORK THEY ARE FORMING. IT PROVIDED A QUALITATIVE PHENOTYPE PREDICTION. CARDIOVASCULAR AND PATHOBIOLOGY PROGRAM BUILDING THE HEART'S POWER STATION. IN TWO SEPARATE STUDIES, DR. DANIEL KELLY'S LABORATORY HAS DEFINED A KEY MECHANISM WHEREBY THE SPECIALIZED MITOCHONDRIAL SYSTEM IN THE HEART IS ESTABLISHED. SPECIFICALLY, USING GENETICALLY ENGINEERED MOUSE MODELS, THE RESEARCH TEAM DEMONSTRATES THAT FACTORS CALLED PGC-1A AND B ARE REQUIRED FOR EQUIPPING THE GROWING HEART WITH A HIGH-CAPACITY MITOCHONDRIAL SYSTEM. THIS INVOLVES A PROCESS CALLED MITOCHONDRIAL DYNAMICS IN WHICH SMALL MITOCHONDRIA UNDERGO REPEATED FUSION FOLLOWED BY SEPARATION TO DISTRIBUTE THROUGHOUT THE HEART CELLS. LOSS OF THE PGC-1 CO-ACTIVATORS DURING THE GROWTH PERIOD FOLLOWING BIRTH PREVENTS THIS PROCESS, LEADING TO AN ENERGY-STARVED FAILING HEART. INTERESTINGLY, IN THE MATURE ADULT HEART, THE PGC-1 CO-ACTIVATORS SERVE A DIFFERENT FUNCTION. IN THE ADULT, THIS PATHWAY IS NECESSARY FOR MAINTAINING THE ENZYMES AND MEMBRANE STRUCTURES OF THE MITOCHONDRIA, PREVENTING WEAR AND TEAR. GIVEN THAT HEART FAILURE IS OFTEN CAUSED BY REDUCED FUNCTION OF MITOCHONDRIA, THIS DISCOVERY COULD BE IMPORTANT AS A FIRST STEP TOWARD THE IDENTIFICATION OF NEW THERAPIES FOR HEART FAILURE. THIS WORK WAS PUBLISHED IN THE JOURNAL OF BIOLOGICAL CHEMISTRY AND CIRCULATION RESEARCH. DISCOVERY OF A NEW MECHANISM LEADING TO ATHEROSCLEROSIS. IN A PAPER PUBLISHED IN ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, DR. DWIGHT TOWLER AND COLLEAGUES DESCRIBED A PATHWAY THAT LEADS TO HARDENING OF ARTERIES (ATHEROSCLEROSIS). THIS WORK ZEROED IN ON A PARTICULARLY DELETERIOUS PROTEIN CALLED DKK1. WHEN FUNCTIONING NORMALLY, DKK1 IS IMPORTANT FOR AIDING IN WOUND REPAIR. BUT INFLAMMATORY RESPONSES TRIGGERED INSIDE ARTERY WALLS ASSOCIATED WITH DISEASES LIKE DIABETES CAN TRIGGER PROLONGED AND DESTRUCTIVE DKK1 ACTIVITY. TOWLER AND HIS TEAM WILL CONTINUE TO STUDY DKK1 TO IDENTIFY POTENTIAL DRUG TARGETS TO PREVENT HARDENING OF ARTERIES IN PATIENTS WITH ATHEROSCLEROSIS. |
| METABOLIC DISEASE PROGRAM | IMAGES OF DEFECTIVE METABOLISM IN TYPE 2 DIABETES. SKELETAL MUSCLE INSULIN RESISTANCE IS THOUGHT TO BE A CRITICAL COMPONENT TO THE DEVELOPMENT OF TYPE 2 DIABETES. UNTIL NOW, HOWEVER, THE SPECIFIC DEFECTS IN MUSCLE THAT CONTRIBUTE TO INSULIN RESISTANCE HAVE NOT BEEN FULLY ELUCIDATED IN HUMANS. IN A PAPER PUBLISHED IN DIABETES, DR. BRET GOODPASTER REPORTS HOW DYNAMIC POSITRON EMISSION TOMOGRAPHY (PET) IMAGING CAN REVEAL WHERE THESE DEFECTS OCCUR IN VIVO. IN THIS STUDY, PATIENTS WITH TYPE 2 DIABETES HAD SEVERE IMPAIRMENTS IN THEIR ABILITY TO TRANSPORT GLUCOSE INTO THE MUSCLE CELLS IN RESPONSE TO INSULIN. THESE STUDIES HIGHLIGHT THE UTILITY OF IN VIVO IMAGING OF METABOLISM USING PET, WHICH CAN ULTIMATELY HELP TO REVEAL SPECIFIC PATHWAYS AND TARGETS TO TREAT DEFECTIVE GLUCOSE METABOLISM IN DIABETES. BACTERIA AND HUMANS ARE MORE ALIKE THAN WE THOUGHT. KEY REGULATORY MECHANISMS HAVE EVOLVED IN DIVERSE ORGANISMS TO MAINTAIN THE PROPER BALANCE OF CELLULAR NUTRIENTS DURING PERIODS OF FEAST OR FAMINE. THIS IS ESSENTIAL BECAUSE OVER ACCUMULATION OF MANY KEY SUBSTANCES CONTRIBUTES TO THE DEVELOPMENT OF A VARIETY OF HUMAN DISEASES. IN A STUDY PUBLISHED IN CELL METABOLISM, DR. TIM OSBORNE'S LAB IDENTIFIED A NEW BRANCH OF METABOLISM THAT ALLOWS CELLS TO DECIDE WHETHER THEY HAVE SUFFICIENT CHOLESTEROL AND FATTY ACIDS. INTERESTINGLY, THIS MECHANISM HAS PROPERTIES HIGHLY REMINISCENT OF PROCESSES FOUND ONLY IN SINGLE-CELLED BACTERIA INDICATING THAT THROUGH EVOLUTION, DIVERSE ORGANISMS HAVE ADAPTED SIMILAR WAYS TO MAINTAIN A HEALTHY BALANCE. STUDYING DIABETES IN A PETRI DISH. IN A PAPER PUBLISHED IN OBESITY, DR. STEVEN SMITH AND COLLEAGUES FOUND THAT MUSCLE STEM CELLS CULTURED IN A DISH FROM PATIENTS WITH METABOLIC DISEASES RETAIN MANY CHARACTERISTICS OF THE DONOR. SUCH "DISEASE IN A DISH" MODELS ARE NOW IN PLACE AT SANFORD-BURNHAM THROUGH A COLLABORATION WITH THE TRANSLATIONAL RESEARCH INSTITUTE FOR METABOLISM AND DIABETES (TRI-MD). THIS EXCITING BREAKTHROUGH ALLOWS RESEARCHERS TO UNDERSTAND BETTER THE PROCESSES THAT LEAD TO OBESITY, DIABETES, AND CARDIOVASCULAR DISEASES. FUTURE STUDIES WILL USE THE ADVANCED TECHNOLOGIES AT SANFORD-BURNHAM TO ACCELERATE THIS LINE OF RESEARCH INCLUDING SCREENING FOR NEW DRUGS. |
| FORM 990, PART VI, LINE 11B | PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE EXECUTIVE VICE PRESIDENT/CHIEF FINANCIAL OFFICER AND CHIEF ADMINISTRATIVE OFFICER, AND THE AUDIT COMMITTEE OF THE BOARD OF TRUSTEES AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. |
| FORM 990, PART VI, QUESTION 12C | DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST CONFLICT OF INTEREST STATEMENTS ARE GIVEN TO TRUSTEES, OFFICERS, AND PRINCIPAL INVESTIGATORS ON A PERIODIC BASIS TO REPORT ON CONFLICTS OR LACK OF CONFLICTS. THE STATEMENTS ARE REVIEWED ANNUALLY BY THE SENIOR DIRECTOR, INTELLECTUAL PROPERTY, DIRECTOR OF ACCOUNTING, AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, WITH A SUMMARY OF THE REVIEW PROVIDED TO THE VP FINANCE/CONTROLLER AND THE EXECUTIVE VICE PRESIDENT/CAO/CFO/TREASURER. AN ASSESSMENT IS MADE TO WHETHER A CONFLICT CAN BE MANAGED BY THE EXISTING DEPARTMENTS AND PRACTICES. CONFLICTS ARE BROUGHT TO THE BOARD OF TRUSTEES ON AN AS NEEDED BASIS. CONFLICTS AND POTENTIAL CONFLICTS THAT INVOLVE THE CEO OR THE PRESIDENT ARE BROUGHT TO THE BOARD OF TRUSTEES TO ADDRESS ANY ACTUAL OR POTENTIAL POSSIBILITY THAT THE DESIGNATED REVIEWERS (I.E., SENIOR DIRECTOR, INTELLECTUAL PROPERTY, DIRECTOR OF ACCOUNTING, THE SENIOR DIRECTOR, SPONSORED RESEARCH, VP FINANCE/CONTOLLER, AND THE EXECUTIVE VICE PRESIDENT/CAO/CFO/TREASURER) COULD BE PRESSURED TO MAKE BIASED DECISIONS IN MANAGING CONFLICTS INVOLVING THE CEO OR PRESIDENT. AS TO RESTRICTIONS IMPOSED: THE INSTITUTE WILL EMPLOY THE MECHANISM THAT IS THE BEST FIT WITH THE FACTS AND CIRCUMSTANCES OF ANY IDENTIFIED CONFLICT OF INTEREST. METHODS TO MANAGE POTENTIAL CONFLICTS/ENFORCEMENT MECHANISM: REVIEWING MANAGEMENT AND THE AUDIT COMMITTEE ARE RESPONSIBLE FOR MANAGING, REDUCING, OR ELIMINATING REAL OR POTENTIAL CONFLICTS OF INTEREST. EXAMPLES OF CONDITIONS OR RESTRICTIONS THAT MIGHT BE IMPOSED TO MANAGE, REDUCE, OR ELIMIATE CONFLICTS OF INTERESTS INCLUDE: -PUBLIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS -MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS -MODIFICATION OF THE RESEARCH PLAN -DISQUALIFICATION FROM PARTICIPATION IN THE PORTION OF FUNDED RESEARCH THAT COULD BE AFFECTED BY SIGNIFICANT FINANCIAL INTEREST -DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS -SEVERENCE OF RELATIONSHIPS THAT CREATE ACTUAL OR POTENTIAL CONFLICTS -REVIEW OF COMMERCIAL SPONSORED RESEARCH AGREEMENTS FOR SCIENTIFIC MERIT BY THE PROGRAM PLANNING COMMITTEE -REMOVAL OF AN AFFECTED PARTY FROM NEGOTIATIONS WITH A COMPANY WITH HE/SHE HAS SIGNIFICANT FINANCIAL INTEREST. |
| FORM 990, PART VI, QUESTION 15A AND 15B | PROCESS USED TO DETERMINE COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, THE EXECUTIVE VICE PRESIDENT/CHIEF FINANCIAL OFFICER/CHIEF ADMINISTRATIVE OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF THREE INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS STUDY WHICH INCLUDES THE CONSULTANT'S OPINION ON THE "REASONABLENESS" OF THE PROPOSED COMPENSATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. IF THE PROPOSAL IS DEEMED TO BE REASONABLE, THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND THEN MAKES A RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF THE PROPOSAL IS DEEMED REASONABLE BY THE EXECUTIVE COMMITTEE, THE COMPENSATION COMMITTEE PRESENTS ITS FINDINGS AND RECOMMENDATIONS TO THE BOARD OF TRUSTEES IN EXECUTIVE SESSION. IF APPROVED BY THE BOARD OF TRUSTEES, THE PROPOSAL IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN OR ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 2, 2014 FOR THE FOLLOWING POSITIONS: 1) INTERIM CEO/PRESIDENT 2) EXECUTIVE VICE PRESIDENT/CAO/CFO/TREASURER 3) SVP EXTERNAL RELATIONS 4) SVP DRUG DISCOVERY & DEVELOPMENT 5) SCIENTIFIC DIRECTOR/PROFESSOR 6) NEUROSCIENCE & AGING AND STEM CELL RESEARCH CENTER DIRECTOR/PROFESSOR 7) CENTER DIRECTOR, LA JOLLA PROFESSOR 8) SCIENTIFIC DIRECTOR/PROFESSOR 9) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR |
| FORM 990, PART VI, LINE 19 | AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY & FIN STMTS TO GEN PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART XI, LINE 5 | OTHER CHANGES IN NET ASSETS OR FUND BALANCES UNREALIZED GAIN (LOSS) ON INTEREST RATE SWAP: 61,784 |
| Software ID: | |
| Software Version: |